These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 23215948)
1. Outcome of poor response paediatric AML using early SCT. Wareham NE; Heilmann C; Abrahamsson J; Forestier E; Gustafsson B; Ha SY; Heldrup J; Jahnukainen K; Jónsson ÓG; Lausen B; Palle J; Zeller B; Hasle H Eur J Haematol; 2013 Mar; 90(3):187-94. PubMed ID: 23215948 [TBL] [Abstract][Full Text] [Related]
2. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J; Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677 [TBL] [Abstract][Full Text] [Related]
3. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987 [TBL] [Abstract][Full Text] [Related]
4. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900 [TBL] [Abstract][Full Text] [Related]
5. Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. Schmid C; Schleuning M; Tischer J; Holler E; Haude KH; Braess J; Haferlach C; Baurmann H; Oruzio D; Hahn J; Spiekermann K; Schlimok G; Schwerdtfeger R; Buechner T; Hiddemann W; Kolb HJ Bone Marrow Transplant; 2012 Jan; 47(1):46-53. PubMed ID: 21358688 [TBL] [Abstract][Full Text] [Related]
6. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
7. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X; Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529 [TBL] [Abstract][Full Text] [Related]
8. [Improved treatment results in children with AML: Results of study AML-BFM 93]. Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M; Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551 [TBL] [Abstract][Full Text] [Related]
9. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients. Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238 [TBL] [Abstract][Full Text] [Related]
10. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440 [TBL] [Abstract][Full Text] [Related]
11. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
12. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446 [TBL] [Abstract][Full Text] [Related]
13. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M; Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916 [TBL] [Abstract][Full Text] [Related]
14. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131 [TBL] [Abstract][Full Text] [Related]
15. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990 [TBL] [Abstract][Full Text] [Related]
18. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491 [TBL] [Abstract][Full Text] [Related]